The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Transthyretin Stabilizer Market Research Report 2024
Synopsis
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.
Global Transthyretin Stabilizer market is projected to reach US$ 2372.8 million in 2029, increasing from US$ 1480 million in 2022, with the CAGR of 6.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Transthyretin Stabilizer market research.
The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.
Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.
One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.
The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.
Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.
Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.
In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Transthyretin Stabilizer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.
Segment by Type
Diflunisal
Tafamidis
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Transthyretin Stabilizer report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.
Global Transthyretin Stabilizer market is projected to reach US$ 2372.8 million in 2029, increasing from US$ 1480 million in 2022, with the CAGR of 6.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Transthyretin Stabilizer market research.
The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.
Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.
One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.
The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.
Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.
Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.
In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Transthyretin Stabilizer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.
Segment by Type
Diflunisal
Tafamidis
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Transthyretin Stabilizer report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Transthyretin Stabilizer Market Overview
1.1 Product Overview and Scope of Transthyretin Stabilizer
1.2 Transthyretin Stabilizer Segment by Type
1.2.1 Global Transthyretin Stabilizer Market Value Comparison by Type (2023-2029)
1.2.2 Diflunisal
1.2.3 Tafamidis
1.2.4 Others
1.3 Transthyretin Stabilizer Segment by Application
1.3.1 Global Transthyretin Stabilizer Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Drug Stores
1.3.5 Online Pharmacies
1.3.6 Others
1.4 Global Transthyretin Stabilizer Market Size Estimates and Forecasts
1.4.1 Global Transthyretin Stabilizer Revenue 2018-2029
1.4.2 Global Transthyretin Stabilizer Sales 2018-2029
1.4.3 Global Transthyretin Stabilizer Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Transthyretin Stabilizer Market Competition by Manufacturers
2.1 Global Transthyretin Stabilizer Sales Market Share by Manufacturers (2018-2023)
2.2 Global Transthyretin Stabilizer Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Transthyretin Stabilizer Average Price by Manufacturers (2018-2023)
2.4 Global Transthyretin Stabilizer Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Transthyretin Stabilizer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Transthyretin Stabilizer, Product Type & Application
2.7 Transthyretin Stabilizer Market Competitive Situation and Trends
2.7.1 Transthyretin Stabilizer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Transthyretin Stabilizer Players Market Share by Revenue
2.7.3 Global Transthyretin Stabilizer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Transthyretin Stabilizer Retrospective Market Scenario by Region
3.1 Global Transthyretin Stabilizer Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Transthyretin Stabilizer Global Transthyretin Stabilizer Sales by Region: 2018-2029
3.2.1 Global Transthyretin Stabilizer Sales by Region: 2018-2023
3.2.2 Global Transthyretin Stabilizer Sales by Region: 2024-2029
3.3 Global Transthyretin Stabilizer Global Transthyretin Stabilizer Revenue by Region: 2018-2029
3.3.1 Global Transthyretin Stabilizer Revenue by Region: 2018-2023
3.3.2 Global Transthyretin Stabilizer Revenue by Region: 2024-2029
3.4 North America Transthyretin Stabilizer Market Facts & Figures by Country
3.4.1 North America Transthyretin Stabilizer Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Transthyretin Stabilizer Sales by Country (2018-2029)
3.4.3 North America Transthyretin Stabilizer Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Transthyretin Stabilizer Market Facts & Figures by Country
3.5.1 Europe Transthyretin Stabilizer Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Transthyretin Stabilizer Sales by Country (2018-2029)
3.5.3 Europe Transthyretin Stabilizer Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Transthyretin Stabilizer Market Facts & Figures by Country
3.6.1 Asia Pacific Transthyretin Stabilizer Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Transthyretin Stabilizer Sales by Country (2018-2029)
3.6.3 Asia Pacific Transthyretin Stabilizer Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Transthyretin Stabilizer Market Facts & Figures by Country
3.7.1 Latin America Transthyretin Stabilizer Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Transthyretin Stabilizer Sales by Country (2018-2029)
3.7.3 Latin America Transthyretin Stabilizer Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Transthyretin Stabilizer Market Facts & Figures by Country
3.8.1 Middle East and Africa Transthyretin Stabilizer Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Transthyretin Stabilizer Sales by Country (2018-2029)
3.8.3 Middle East and Africa Transthyretin Stabilizer Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Transthyretin Stabilizer Sales by Type (2018-2029)
4.1.1 Global Transthyretin Stabilizer Sales by Type (2018-2023)
4.1.2 Global Transthyretin Stabilizer Sales by Type (2024-2029)
4.1.3 Global Transthyretin Stabilizer Sales Market Share by Type (2018-2029)
4.2 Global Transthyretin Stabilizer Revenue by Type (2018-2029)
4.2.1 Global Transthyretin Stabilizer Revenue by Type (2018-2023)
4.2.2 Global Transthyretin Stabilizer Revenue by Type (2024-2029)
4.2.3 Global Transthyretin Stabilizer Revenue Market Share by Type (2018-2029)
4.3 Global Transthyretin Stabilizer Price by Type (2018-2029)
5 Segment by Application
5.1 Global Transthyretin Stabilizer Sales by Application (2018-2029)
5.1.1 Global Transthyretin Stabilizer Sales by Application (2018-2023)
5.1.2 Global Transthyretin Stabilizer Sales by Application (2024-2029)
5.1.3 Global Transthyretin Stabilizer Sales Market Share by Application (2018-2029)
5.2 Global Transthyretin Stabilizer Revenue by Application (2018-2029)
5.2.1 Global Transthyretin Stabilizer Revenue by Application (2018-2023)
5.2.2 Global Transthyretin Stabilizer Revenue by Application (2024-2029)
5.2.3 Global Transthyretin Stabilizer Revenue Market Share by Application (2018-2029)
5.3 Global Transthyretin Stabilizer Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer Inc.
6.1.1 Pfizer Inc. Corporation Information
6.1.2 Pfizer Inc. Description and Business Overview
6.1.3 Pfizer Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Inc. Transthyretin Stabilizer Product Portfolio
6.1.5 Pfizer Inc. Recent Developments/Updates
6.2 Merck & Co.
6.2.1 Merck & Co. Corporation Information
6.2.2 Merck & Co. Description and Business Overview
6.2.3 Merck & Co. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co. Transthyretin Stabilizer Product Portfolio
6.2.5 Merck & Co. Recent Developments/Updates
6.3 AstraZeneca Plc.
6.3.1 AstraZeneca Plc. Corporation Information
6.3.2 AstraZeneca Plc. Description and Business Overview
6.3.3 AstraZeneca Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AstraZeneca Plc. Transthyretin Stabilizer Product Portfolio
6.3.5 AstraZeneca Plc. Recent Developments/Updates
6.4 GlaxoSmithKline Plc.
6.4.1 GlaxoSmithKline Plc. Corporation Information
6.4.2 GlaxoSmithKline Plc. Description and Business Overview
6.4.3 GlaxoSmithKline Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxoSmithKline Plc. Transthyretin Stabilizer Product Portfolio
6.4.5 GlaxoSmithKline Plc. Recent Developments/Updates
6.5 Corino Therapeutics Inc.
6.5.1 Corino Therapeutics Inc. Corporation Information
6.5.2 Corino Therapeutics Inc. Description and Business Overview
6.5.3 Corino Therapeutics Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Corino Therapeutics Inc. Transthyretin Stabilizer Product Portfolio
6.5.5 Corino Therapeutics Inc. Recent Developments/Updates
6.6 Alnylam Pharmaceuticals
6.6.1 Alnylam Pharmaceuticals Corporation Information
6.6.2 Alnylam Pharmaceuticals Description and Business Overview
6.6.3 Alnylam Pharmaceuticals Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Alnylam Pharmaceuticals Transthyretin Stabilizer Product Portfolio
6.6.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.7 Bellus Health Inc.
6.6.1 Bellus Health Inc. Corporation Information
6.6.2 Bellus Health Inc. Description and Business Overview
6.6.3 Bellus Health Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bellus Health Inc. Transthyretin Stabilizer Product Portfolio
6.7.5 Bellus Health Inc. Recent Developments/Updates
6.8 Ionis Pharmaceuticals, Inc.
6.8.1 Ionis Pharmaceuticals, Inc. Corporation Information
6.8.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
6.8.3 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Product Portfolio
6.8.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
6.9 Proclara Bioscience
6.9.1 Proclara Bioscience Corporation Information
6.9.2 Proclara Bioscience Description and Business Overview
6.9.3 Proclara Bioscience Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Proclara Bioscience Transthyretin Stabilizer Product Portfolio
6.9.5 Proclara Bioscience Recent Developments/Updates
6.10 Arturus Therapeutics
6.10.1 Arturus Therapeutics Corporation Information
6.10.2 Arturus Therapeutics Description and Business Overview
6.10.3 Arturus Therapeutics Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Arturus Therapeutics Transthyretin Stabilizer Product Portfolio
6.10.5 Arturus Therapeutics Recent Developments/Updates
6.11 Prothena Corporation Plc.
6.11.1 Prothena Corporation Plc. Corporation Information
6.11.2 Prothena Corporation Plc. Transthyretin Stabilizer Description and Business Overview
6.11.3 Prothena Corporation Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Prothena Corporation Plc. Transthyretin Stabilizer Product Portfolio
6.11.5 Prothena Corporation Plc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Transthyretin Stabilizer Industry Chain Analysis
7.2 Transthyretin Stabilizer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Transthyretin Stabilizer Production Mode & Process
7.4 Transthyretin Stabilizer Sales and Marketing
7.4.1 Transthyretin Stabilizer Sales Channels
7.4.2 Transthyretin Stabilizer Distributors
7.5 Transthyretin Stabilizer Customers
8 Transthyretin Stabilizer Market Dynamics
8.1 Transthyretin Stabilizer Industry Trends
8.2 Transthyretin Stabilizer Market Drivers
8.3 Transthyretin Stabilizer Market Challenges
8.4 Transthyretin Stabilizer Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
